tofacitinib Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
Janus kinase inhibitors, antineoplastics 4713 477600-75-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tasocitinib
  • xeljanz
  • CP 690550
  • tofacitinib citrate
  • tofacitinib
  • CP-690550
Tofacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.
  • Molecular weight: 312.38
  • Formula: C16H20N6O
  • CLOGP: 1.55
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 88.91
  • ALOGS: -3.02
  • ROTB: 3

Drug dosage:

DoseUnitRoute
10 mg O

Approvals:

DateAgencyCompanyOrphan
Nov. 6, 2012 FDA PF PRISM CV

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Arthralgia 5798.94 42.50 1905 11734 58956 3313264
Musculoskeletal stiffness 4299.43 42.50 1096 12543 12854 3359366
Drug ineffective 4173.88 42.50 1781 11858 114309 3257911
Joint swelling 3914.89 42.50 1061 12578 15996 3356224
Condition aggravated 2592.09 42.50 943 12696 38290 3333930
Fatigue 2414.90 42.50 1197 12442 106043 3266177
Synovitis 2273.96 42.50 452 13187 1393 3370827
Pain 2231.72 42.50 1002 12637 70555 3301665
Headache 2087.15 42.50 1034 12605 90946 3281274
Peripheral swelling 2020.35 42.50 629 13010 15503 3356717
Pain in extremity 2019.52 42.50 838 12801 48374 3323846
Rheumatoid arthritis 1992.96 42.50 618 13021 15020 3357200
Joint range of motion decreased 1719.85 42.50 370 13269 1840 3370380
Herpes zoster 1118.27 42.50 369 13270 10903 3361317
Tenderness 1075.35 42.50 258 13381 2228 3369992
Back pain 1019.12 42.50 482 13157 37523 3334697
Swelling 964.44 42.50 379 13260 18665 3353555
Musculoskeletal pain 942.37 42.50 333 13306 12133 3360087
Diarrhoea 941.63 42.50 648 12991 103700 3268520
Drug effect incomplete 933.25 42.50 295 13344 7555 3364665
Nausea 918.89 42.50 695 12944 128950 3243270
Nasopharyngitis 878.64 42.50 369 13270 21578 3350642
Abdominal discomfort 873.06 42.50 352 13287 18532 3353688
Joint stiffness 845.34 42.50 242 13397 4360 3367860
Sinusitis 804.11 42.50 321 13318 16447 3355773
Cough 741.65 42.50 395 13244 39463 3332757
Weight increased 733.49 42.50 345 13294 26395 3345825
Rash 703.91 42.50 468 13171 70353 3301867
Dry mouth 676.17 42.50 245 13394 9577 3362643
Upper respiratory tract infection 669.00 42.50 242 13397 9413 3362807
Dry eye 655.79 42.50 192 13447 3750 3368470
Alopecia 640.20 42.50 283 13356 18703 3353517
Myalgia 636.28 42.50 332 13307 31743 3340477
Arthropathy 603.93 42.50 212 13427 7539 3364681
Abdominal pain upper 593.56 42.50 292 13347 24624 3347596
Malaise 590.44 42.50 407 13232 64770 3307450
Rhinorrhoea 552.28 42.50 198 13441 7491 3364729
Blood cholesterol increased 550.51 42.50 194 13445 6975 3365245
Urinary tract infection 547.10 42.50 298 13341 31030 3341190
Loss of personal independence in daily activities 543.68 42.50 178 13461 5092 3367128
Oropharyngeal pain 537.00 42.50 220 13419 12014 3360206
Neck pain 505.18 42.50 192 13447 8575 3363645
Joint noise 504.55 42.50 111 13528 617 3371603
Infection 466.58 42.50 250 13389 25152 3347068
Drug dose omission 462.21 42.50 287 13352 38145 3334075
Muscle spasms 447.61 42.50 248 13391 26655 3345565
Insomnia 444.12 42.50 273 13366 35625 3336595
Hypoaesthesia 417.83 42.50 231 13408 24708 3347512
Bronchitis 401.50 42.50 190 13449 14655 3357565
Pneumonia 400.93 42.50 333 13306 69810 3302410
Contusion 378.20 42.50 183 13456 14827 3357393
Blood pressure increased 372.53 42.50 206 13433 22024 3350196
Fall 370.96 42.50 296 13343 58587 3313633
Dyspepsia 364.15 42.50 166 13473 11746 3360474
Abdominal pain 353.80 42.50 261 13378 45964 3326256
Paraesthesia 351.94 42.50 214 13425 27334 3344886
Dizziness 349.96 42.50 320 13319 76192 3296028
Dyspnoea 343.18 42.50 362 13277 102572 3269648
Sleep disorder 342.54 42.50 143 13496 8170 3364050
Arthritis 342.28 42.50 154 13485 10564 3361656
Fibromyalgia 340.38 42.50 108 13531 2781 3369439
Nasal congestion 340.11 42.50 138 13501 7329 3364891
Hand deformity 321.76 42.50 80 13559 807 3371413
Treatment failure 312.38 42.50 125 13514 6399 3365821
Grip strength decreased 294.18 42.50 78 13561 1035 3371185
Influenza 293.99 42.50 146 13493 12500 3359720
Gait disturbance 293.67 42.50 192 13447 27800 3344420
Red blood cell sedimentation rate increased 280.92 42.50 91 13548 2507 3369713
Depression 276.19 42.50 212 13427 39558 3332662
Asthenia 275.56 42.50 262 13377 65403 3306817
Product use issue 267.11 42.50 148 13491 15853 3356367
Osteoarthritis 258.71 42.50 115 13524 7655 3364565
Therapeutic response unexpected 257.75 42.50 102 13537 5066 3367154
Drug hypersensitivity 256.06 42.50 194 13445 35486 3336734
Drug intolerance 255.96 42.50 130 13509 11668 3360552
Hepatic enzyme increased 252.30 42.50 135 13504 13490 3358730
Crepitations 248.12 42.50 66 13573 887 3371333
Muscular weakness 229.17 42.50 146 13493 20195 3352025
Constipation 226.48 42.50 170 13469 30642 3341578
Pyrexia 224.24 42.50 259 13380 80856 3291364
Nodule 222.35 42.50 75 13564 2349 3369871
Diverticulitis 217.22 42.50 90 13549 5035 3367185
Joint effusion 216.12 42.50 66 13573 1490 3370730
Foot deformity 213.56 42.50 70 13569 2002 3370218
Anxiety 204.94 42.50 178 13461 39451 3332769
Pre-existing condition improved 204.42 42.50 50 13589 468 3371752
Synovial disorder 203.97 42.50 38 13601 71 3372149
Drug effect decreased 203.22 42.50 112 13527 11857 3360363
Liver function test increased 190.80 42.50 63 13576 1844 3370376
Vomiting 180.28 42.50 244 13395 89287 3282933
Hypertension 177.44 42.50 162 13477 38304 3333916
Cystitis 170.84 42.50 77 13562 5289 3366931
Gastric disorder 164.65 42.50 68 13571 3770 3368450
C-reactive protein increased 162.55 42.50 89 13550 9294 3362926
Gastrointestinal disorder 155.32 42.50 90 13549 10479 3361741
C-reactive protein abnormal 153.56 42.50 37 13602 323 3371897
Musculoskeletal discomfort 152.25 42.50 57 13582 2429 3369791
Viral upper respiratory tract infection 151.51 42.50 52 13587 1717 3370503
Acne 149.55 42.50 64 13575 3879 3368341
Nodal osteoarthritis 148.91 42.50 29 13610 76 3372144
Bursitis 148.81 42.50 54 13585 2105 3370115
Localised infection 147.38 42.50 61 13578 3400 3368820
Osteoporosis 147.33 42.50 67 13572 4698 3367522
Chest pain 146.74 42.50 149 13490 40126 3332094
Night sweats 145.00 42.50 66 13573 4637 3367583
Erythema 143.98 42.50 127 13512 28683 3343537
Weight decreased 143.60 42.50 147 13492 39964 3332256
Product use in unapproved indication 143.04 42.50 61 13578 3665 3368555
Feeling abnormal 142.90 42.50 124 13515 27401 3344819
Abdominal distension 141.85 42.50 93 13546 13483 3358737
Intentional product misuse 137.59 42.50 89 13550 12612 3359608
Migraine 135.88 42.50 81 13558 9935 3362285
Limb discomfort 133.86 42.50 57 13582 3411 3368809
Red blood cell sedimentation rate abnormal 132.40 42.50 30 13609 194 3372026
Rheumatoid nodule 132.26 42.50 35 13604 460 3371760
Pruritus 131.53 42.50 151 13488 46682 3325538
Fungal infection 131.29 42.50 66 13573 5783 3366437
Mobility decreased 131.19 42.50 79 13560 9869 3362351
Dry skin 129.26 42.50 72 13567 7771 3364449
Disease recurrence 129.18 42.50 63 13576 5171 3367049
Flatulence 127.22 42.50 65 13574 5894 3366326
Chills 126.14 42.50 105 13534 21917 3350303
Increased tendency to bruise 125.39 42.50 46 13593 1850 3370370
Gastrooesophageal reflux disease 124.36 42.50 81 13558 11610 3360610
Mouth ulceration 123.19 42.50 58 13581 4402 3367818
Joint laxity 122.37 42.50 21 13618 17 3372203
Viral infection 118.55 42.50 62 13577 5900 3366320
Oedema peripheral 117.66 42.50 123 13516 34238 3337982
Tooth infection 116.39 42.50 45 13594 2095 3370125
Sinus disorder 116.07 42.50 48 13591 2668 3369552
Sjogren's syndrome 114.91 42.50 36 13603 886 3371334
Productive cough 114.68 42.50 62 13577 6309 3365911
Hypersensitivity 114.13 42.50 110 13529 27790 3344430
Sensitivity to weather change 112.84 42.50 26 13613 183 3372037
Hair growth abnormal 112.79 42.50 33 13606 639 3371581
Oral herpes 109.77 42.50 43 13596 2074 3370146
Nail disorder 108.27 42.50 37 13602 1205 3371015
Kidney infection 107.96 42.50 44 13595 2356 3369864
Interstitial lung disease 106.54 42.50 79 13560 13937 3358283
Influenza like illness 105.45 42.50 80 13559 14607 3357613
Stress 105.34 42.50 62 13577 7424 3364796
Hot flush 105.23 42.50 62 13577 7439 3364781
Bone erosion 104.37 42.50 28 13611 389 3371831
Synovial cyst 101.03 42.50 33 13606 932 3371288
Liver function test abnormal 100.95 42.50 74 13565 12827 3359393
Lipids increased 100.87 42.50 28 13611 445 3371775
Immune system disorder 100.13 42.50 38 13601 1681 3370539
Cataract 99.84 42.50 59 13580 7117 3365103
Pollakiuria 98.16 42.50 53 13586 5377 3366843
Memory impairment 97.72 42.50 77 13562 14861 3357359
Therapy cessation 95.14 42.50 46 13593 3703 3368517
Stomatitis 95.03 42.50 69 13570 11783 3360437
Inflammation 94.97 42.50 58 13581 7427 3364793
Trigger finger 93.77 42.50 27 13612 493 3371727
Lower respiratory tract infection 93.22 42.50 55 13584 6614 3365606
Finger deformity 93.01 42.50 30 13609 813 3371407
Intentional product use issue 92.75 42.50 37 13602 1873 3370347
Arthritis bacterial 92.55 42.50 33 13606 1221 3370999
Bone disorder 92.17 42.50 47 13592 4242 3367978
Joint injury 90.65 42.50 41 13598 2836 3369384
Blister 89.18 42.50 59 13580 8675 3363545
Hyperhidrosis 87.08 42.50 88 13551 23522 3348698
Cellulitis 86.97 42.50 67 13572 12508 3359712
Poor quality sleep 84.19 42.50 37 13602 2390 3369830
Anaemia 84.14 42.50 131 13508 54202 3318018
Spinal pain 83.36 42.50 31 13608 1295 3370925
Eye infection 82.18 42.50 31 13608 1348 3370872
Carpal tunnel syndrome 81.66 42.50 36 13603 2343 3369877
Limb injury 81.26 42.50 38 13601 2838 3369382
Joint dislocation 79.72 42.50 32 13607 1646 3370574
Joint contracture 79.23 42.50 22 13617 350 3371870
Tinnitus 78.87 42.50 51 13588 7214 3365006
Ear infection 78.38 42.50 39 13600 3340 3368880
Laryngitis 78.34 42.50 30 13609 1360 3370860
Drug ineffective for unapproved indication 77.94 42.50 39 13600 3381 3368839
Onychomycosis 76.67 42.50 25 13614 702 3371518
Wheezing 75.77 42.50 52 13587 8119 3364101
Back disorder 74.54 42.50 32 13607 1952 3370268
Skin disorder 74.36 42.50 42 13597 4651 3367569
Nephrolithiasis 74.23 42.50 48 13591 6788 3365432
Rheumatoid factor positive 73.92 42.50 19 13620 221 3371999
Soft tissue disorder 72.87 42.50 20 13619 304 3371916
Tooth abscess 72.06 42.50 33 13606 2349 3369871
Palpitations 71.95 42.50 72 13567 19011 3353209
Respiratory tract infection 71.23 42.50 41 13598 4707 3367513
Sepsis 69.13 42.50 91 13548 32282 3339938
Soft tissue swelling 68.84 42.50 14 13625 49 3372171
Asthma 68.62 42.50 58 13581 12344 3359876
Swelling face 68.59 42.50 56 13583 11360 3360860
Joint warmth 68.15 42.50 19 13620 307 3371913
Burning sensation 64.99 42.50 49 13590 8855 3363365
Sinus congestion 64.16 42.50 30 13609 2239 3369981
Gastroenteritis viral 62.83 42.50 31 13608 2607 3369613
Feeling hot 61.39 42.50 45 13594 7791 3364429
Ocular hyperaemia 60.46 42.50 38 13601 5115 3367105
Temperature intolerance 60.36 42.50 23 13616 1028 3371192
Decreased appetite 59.99 42.50 97 13542 41393 3330827
Pelvic fracture 59.97 42.50 25 13614 1417 3370803
Staphylococcal infection 59.94 42.50 46 13593 8533 3363687
Blood triglycerides increased 59.61 42.50 36 13603 4514 3367706
Skin lesion 58.62 42.50 38 13601 5395 3366825
Respiratory tract congestion 58.51 42.50 30 13609 2737 3369483
Middle insomnia 58.42 42.50 26 13613 1730 3370490
Lung infection 57.86 42.50 38 13601 5515 3366705
Seasonal allergy 57.80 42.50 25 13614 1553 3370667
Blood glucose increased 57.48 42.50 64 13575 19091 3353129
Oral pain 57.27 42.50 33 13606 3795 3368425
Low density lipoprotein increased 57.20 42.50 26 13613 1818 3370402
Ulcer 57.16 42.50 28 13611 2318 3369902
Dysphonia 56.33 42.50 42 13597 7462 3364758
White blood cell count decreased 56.17 42.50 72 13567 24875 3347345
Wrist deformity 55.29 42.50 13 13626 101 3372119
Tendon rupture 55.13 42.50 29 13610 2789 3369431
Oedema 54.62 42.50 55 13584 14625 3357595
Bone swelling 54.59 42.50 15 13624 229 3371991
Visual impairment 54.47 42.50 54 13585 14092 3358128
Impaired work ability 54.42 42.50 27 13612 2297 3369923
Skin ulcer 53.72 42.50 36 13603 5404 3366816
Appendicitis 53.35 42.50 25 13614 1875 3370345
Drug effect delayed 53.32 42.50 18 13621 564 3371656
Movement disorder 53.20 42.50 31 13608 3640 3368580
Vision blurred 52.94 42.50 62 13577 19527 3352693
Ophthalmic herpes zoster 52.63 42.50 16 13623 355 3371865
Femur fracture 52.46 42.50 40 13599 7348 3364872
Sciatica 52.16 42.50 26 13613 2234 3369986
Urticaria 51.16 42.50 74 13565 28653 3343567
Drug effect variable 50.83 42.50 13 13626 148 3372072
Skin discolouration 49.49 42.50 37 13602 6599 3365621
Laboratory test abnormal 49.06 42.50 35 13604 5809 3366411
Osteomyelitis 48.92 42.50 33 13606 5007 3367213
Skin mass 48.86 42.50 21 13618 1284 3370936
Balance disorder 48.85 42.50 48 13591 12391 3359829
Pulmonary mass 48.81 42.50 25 13614 2275 3369945
Herpes virus infection 48.61 42.50 20 13619 1096 3371124
Epistaxis 48.09 42.50 51 13588 14400 3357820
Impaired healing 47.98 42.50 37 13602 6911 3365309
Lung disorder 47.88 42.50 41 13598 8876 3363344
Nerve compression 47.50 42.50 20 13619 1162 3371058
Hernia 47.35 42.50 23 13616 1869 3370351
Depressed mood 47.25 42.50 36 13603 6605 3365615
Non-Hodgkin's lymphoma 47.19 42.50 22 13617 1631 3370589
Rheumatoid factor increased 46.91 42.50 14 13625 291 3371929
Bone pain 46.64 42.50 42 13597 9719 3362501
Rib fracture 46.43 42.50 28 13611 3501 3368719
Dysphagia 46.26 42.50 58 13581 19593 3352627
Spinal column stenosis 46.13 42.50 22 13617 1716 3370504
Coeliac disease 45.52 42.50 19 13620 1080 3371140
Therapeutic response decreased 45.24 42.50 43 13596 10655 3361565
Amnesia 45.15 42.50 43 13596 10683 3361537
Photosensitivity reaction 45.11 42.50 27 13612 3330 3368890
Joint lock 44.10 42.50 15 13624 481 3371739
Synovial fluid analysis 44.00 42.50 7 13632 1 3372219
Onychomadesis 43.93 42.50 15 13624 487 3371733
Sinus pain 43.52 42.50 11 13628 119 3372101
Pain in jaw 43.46 42.50 33 13606 6025 3366195
Arthritis infective 43.24 42.50 17 13622 827 3371393
Flank pain 42.79 42.50 22 13617 2018 3370202
Scleritis 42.57 42.50 13 13626 293 3371927

Pharmacologic Action:

SourceCodeDescription
ATC L04AA29 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Selective immunosuppressants
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:35842 antirheumatic drug
FDA EPC N0000190858 Janus Kinase Inhibitor
FDA MoA N0000190857 Janus Kinase Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Rheumatoid arthritis indication 69896004 DOID:7148

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.27 acidic
pKa2 6.48 Basic
pKa3 0.91 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 5MG BASE XELJANZ PF PRISM CV N203214 Nov. 6, 2012 RX TABLET ORAL 7091208 Dec. 8, 2020 TREATMENT OF RHEUMATOID ARTHRITIS
EQ 11MG BASE XELJANZ XR PFIZER INC N208246 Feb. 23, 2016 RX TABLET, EXTENDED RELEASE ORAL 7091208 Dec. 8, 2020 TREATMENT OF RHEUMATOID ARTHRITIS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 5MG BASE XELJANZ PF PRISM CV N203214 Nov. 6, 2012 RX TABLET ORAL Dec. 14, 2020 TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE OR OTHER NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
EQ 11MG BASE XELJANZ XR PFIZER INC N208246 Feb. 23, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 14, 2020 TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE OR OTHER NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
JAK2/TYK2 Kinase INHIBITOR IC50 6.64 CHEMBL CHEMBL
JAK1/TYK2 Kinase INHIBITOR IC50 7.46 CHEMBL CHEMBL
JAK2/JAK1 Kinase INHIBITOR IC50 6.39 DRUG LABEL DRUG LABEL
JAK3/JAK1 Kinase INHIBITOR IC50 7.25 DRUG LABEL DRUG LABEL
Tyrosine-protein kinase JAK2 Kinase INHIBITOR Kd 9.24 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 6.27 CHEMBL
Ribosomal protein S6 kinase alpha-1 Kinase Kd 5.85 CHEMBL
JAK1/JAK2/TYK2 Kinase INHIBITOR IC50 7.12 CHEMBL
Tyrosine-protein kinase JAK1 Kinase INHIBITOR Ki 9.17 CHEMBL
G protein-coupled receptor kinase 7 Kinase Kd 5.37 CHEMBL
Serine/threonine-protein kinase N2 Kinase Kd 5.92 CHEMBL
Rho-associated protein kinase 1 Kinase Kd 6.33 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 6.26 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 5.15 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 5.80 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase INHIBITOR Ki 8.36 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 5.80 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 5.37 CHEMBL
Tyrosine-protein kinase JAK3 Kinase INHIBITOR IC50 8.48 WOMBAT-PK
Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase Kd 5.46 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 5.19 CHEMBL
Rho-associated protein kinase 2 Kinase Kd 6.38 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.96 CHEMBL
Protein kinase C delta type Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase DCLK3 Kinase Kd 8.35 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 5.48 CHEMBL
Myotonin-protein kinase Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 6.34 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 6.62 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 6.77 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 5.32 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.92 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 6.22 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 5.66 CHEMBL
Serine/threonine-protein kinase DCLK1 Kinase Kd 5.17 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase PknB Kinase Kd 5.70 CHEMBL
Tyrosine-protein kinase JAK3 Kinase IC50 7.32 CHEMBL
Tyrosine-protein kinase JAK2 Kinase IC50 5.69 CHEMBL

External reference:

IDSource
5677 IUPHAR_LIGAND_ID
D09783 KEGG_DRUG
4031786 VUID
N0000186059 NUI
C2930696 UMLSCUI
87LA6FU830 UNII
9298 INN_ID
CHEMBL221959 ChEMBL_ID
CHEMBL459769 ChEMBL_ID
C479163 MESH_SUPPLEMENTAL_RECORD_UI
DB08895 DRUGBANK_ID
CHEMBL2103743 ChEMBL_ID
540737-29-9 SECONDARY_CAS_RN
1357536 RXNORM
28976 MMSL
d07925 MMSL
014743 NDDF
4031786 VANDF
N0000186059 NDFRT
704313003 SNOMEDCT_US
704316006 SNOMEDCT_US
9926791 PUBCHEM_CID
CHEBI:71200 CHEBI
MI1 PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
XELJANZ HUMAN PRESCRIPTION DRUG LABEL 1 0069-0501 TABLET, FILM COATED, EXTENDED RELEASE 11 mg ORAL NDA 20 sections
XELJANZ HUMAN PRESCRIPTION DRUG LABEL 1 0069-1001 TABLET, FILM COATED 5 mg ORAL NDA 20 sections
XELJANZ HUMAN PRESCRIPTION DRUG LABEL 1 63539-012 TABLET, FILM COATED 5 mg ORAL NDA 20 sections
XELJANZ HUMAN PRESCRIPTION DRUG LABEL 1 63539-501 TABLET, EXTENDED RELEASE 11 mg ORAL NDA 20 sections